Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc reported that Gregory L. Smith, Executive Vice President, Enterprise Operations, will retire from the company effective December 2, 2025 and plans to join a private equity‑held organization. The company states he will receive retirement treatment for outstanding equity as previously disclosed.
Under those equity terms, unvested stock options will accelerate, while restricted stock units (RSUs) and performance stock units (PSUs) will continue to vest in line with the applicable award agreements filed with the SEC.
Medtronic plc reported the results of its Annual General Meeting held on October 16, 2025. Shareholders approved amendments to the company’s Memorandum and Articles of Association, including changes to Article 177 to allow the Board to capitalize certain non-distributable reserves to create distributable reserves and updates to the advance notice provisions. They also approved a capital reduction to create distributable reserves under Irish law.
All twelve director nominees were elected and shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 and authorized the Board, through the Audit Committee, to set auditor remuneration. Shareholders renewed the Board’s authority to issue shares and to opt out of pre-emption rights under Irish law, and authorized the company and its subsidiaries to make overseas market purchases of ordinary shares. At the record date, 1,282,616,011 ordinary shares were outstanding; 1,109,198,321 were represented at the meeting, constituting a quorum.
Medtronic plc (MDT) appears on a Form 25 notification indicating the class of securities is being removed from listing and/or registration on the New York Stock Exchange LLC. The filing identifies the issuer's principal office at 710 Medtronic Pkwy, Minneapolis, MN and includes the Commission File Number 001-36820. The form cites compliance with 17 CFR 240.12d2-2 provisions for withdrawal or removal. The document provides no explanation of timing, underlying transaction, or impact on shareholders.
Medtronic plc filed an 8-K disclosing a Sixth Supplemental Indenture dated September 29, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Computershare Trust Company, N.A. as successor trustee and U.S. Bank Europe DAC, UK Branch as paying agent. The filing includes the forms of the 2030 Notes and the 2045 Notes, and attaches legal opinions from U.S., Irish and Luxembourg counsel plus consents from each counsel and an internal opinion by an Assistant Secretary. The submission also references an embedded Cover Page Interactive Data File and is signed by Thierry Pi e9ton, Executive Vice President and Chief Financial Officer.
Medtronic plc filed an 8-K disclosing an Underwriting Agreement dated September 15, 2025 among Medtronic, Inc., Medtronic plc and Medtronic Global Holdings S.C.A., with Deutsche Bank AG, London Branch and Goldman Sachs & Co. LLC named as the representatives of the several underwriters. The filing also notes an embedded Cover Page Interactive Data File with the Inline XBRL document. The filing is signed on September 16, 2025 by Thierry Piéton, Executive Vice President and Chief Financial Officer.
The notice identifies the existence and date of the underwriting arrangement and the lead underwriters but does not disclose transaction size, terms, or intended use of proceeds.
Medtronic plc is offering debt securities, including $750,000,000 aggregate principal amount of 4.200% senior notes due October 15, 2045. The prospectus supplement states certain pricing rows showing prices to investors near 99.97% with underwriting discounts of 0.35% and 0.65%, producing proceeds to Medtronic, Inc. around 99.62% and 99.25% respectively. As of July 25, 2025, the company reported approximately $28.6 billion of debt outstanding, including $27.8 billion aggregate principal of senior debt of Medtronic plc, Medtronic Luxco and Medtronic, Inc.
The supplement explains that Medtronic Luxco and Medtronic, Inc. are wholly‑owned indirect subsidiaries of Medtronic plc and that notes issued by Medtronic, Inc. will be fully and unconditionally guaranteed on a joint and several basis by Medtronic plc and Medtronic Luxco. The indenture does not prohibit additional unsecured indebtedness or significant secured indebtedness and certain tax, withholding and investor eligibility provisions are described. Financial statements for Luxco and Medtronic, Inc. are not separately included; Medtronic plc provides alternative summarized disclosure under Regulation S‑X.
Medtronic insider stock sales reported. The reporting person, EVP & President Cardiovascular Harry "Skip" Kiil, sold a total of 8,605 ordinary shares in two transactions on 09/03/2025 at prices of about $91.58 and $91.59. After these dispositions the reporting person beneficially owns 35,615 ordinary shares, held directly. The Form 4 was submitted to disclose these non-derivative sales and the change in beneficial ownership.
Medtronic (MDT) Form 144 summary: The filing notifies an intended sale of 8,605 shares of Medtronic common stock held at Fidelity Brokerage Services, with an aggregate market value of $788,048.74. The shares were acquired on 08/01/2025 through restricted stock vesting from the issuer as compensation and the filer lists an approximate sale date of 09/03/2025 on the NYSE. The filing states there were no other securities sold by the same person in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Medtronic (MDT) reported first-quarter fiscal 2026 operating details showing continued product-driven revenue growth across core portfolios and ongoing corporate actions. The company announced in May 2025 its intent to separate the Diabetes Operating Unit into a standalone public company, expected within 18 months. Cardiovascular net sales were up, with Cardiac Rhythm & Heart Failure rising 12%, Structural Heart & Aortic up 9%, and Coronary & Peripheral Vascular up 5%. Medical Surgical net sales were $2.1 billion, up 4% year-over-year. Research and development expense was $726 million versus $676 million a year earlier, and selling, general, and administrative expense was $2.8 billion versus $2.7 billion. The company recognized a $90 million fair-value loss on its Mozarc investment and recorded restructuring charges of $67 million. Deferred revenue was $442 million. Total debt was $28.6 billion while liquidity included $1.3 billion cash and $6.8 billion of current investments. Accrued litigation was approximately $0.2 billion; legal and tax matters remain disclosed as potentially material.
William R. Jellison, a director of Medtronic plc (MDT), reported two open-market purchases of ordinary shares. He acquired 2,500 shares on 08/22/2025 at $92.73 per share and 2,500 shares on 08/25/2025 at $92.37 per share, bringing his reported direct beneficial ownership to 5,000 shares. The filing notes the shares are held in a joint account with his spouse. The Form 4 was executed by an attorney-in-fact on 08/25/2025. No derivative transactions or dispositions are reported in this filing.